Search company, investor...


Founded Year



Loan | Alive

Total Raised


Last Raised

$21.26M | 6 mos ago

About Affibody

Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.

Headquarters Location

Scheeles väg 2

Solna, 171 65,


46 (0)8 59 88 38 00

Missing: Affibody's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Affibody's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Affibody Patents

Affibody has filed 53 patents.

The 3 most popular patent topics include:

  • Proteins
  • Transcription factors
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Radiopharmaceuticals, Immunology


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Monoclonal antibodies, Monoclonal antibodies for tumors, Radiopharmaceuticals, Immunology



Latest Affibody News

Patients see atopic dermatitis improvement with switch from dupilumab to upadacitinib

May 31, 2023

Disclosures: Blauvelt reports being a speaker, advisor or investigator for AbbVie, Abcentra, Acelyrin, Affibody, Aligos, Almirall, Alumis, AnaptysBio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Concert, Dermavant, EcoR1, Eli Lilly, Escient, EVELO, Evommune, Forte, Galderma, Highlightll Pharma, Incyte, Innovent Bio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB, Vibliome and Xencor. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Patients with continuous upadacitinib maintained EASI improvements. The percentage of patients that switched to upadacitinib from dupilumab and achieved EASI 90 increased from 66.4% to 87.8% after 4 weeks. Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment, according to a study. “Dupilumab was the first biologic approved to treat [atopic dermatitis (AD)]; however, after 16 weeks of treatment, fewer than 40% of patients achieve clear or almost clear skin and maximal response is not observed until after week 12,” Andrew Blauvelt, MD, MBA, investigator at the Oregon Medical Research Center, and colleagues wrote. Patients with moderate to severe atopic dermatitis that switched from dupilumab to upadacitinib experienced significant improvement in efficacy and itch as early as week 4 of treatment. While dupilumab is still regarded as a highly effective biologic in this indication, according to the study, there are other treatment options available such as upadacitinib, an oral, selective Janus kinase inhibitor that is also approved to treat adolescents and adults with moderate to severe AD . In this 16-week interim analysis of a 52-week open label extension (OLE) study of 484 adults with moderate to severe AD who completed the phase 3b Heads Up trial, researchers evaluated the long-term safety and efficacy of continuous upadacitinib at 30 mg and of switching to upadacitinib after 24 weeks of dupilumab. After 24 weeks of receiving once-daily upadacitinib 30 mg, 239 patients continued the same dosage. Additionally, 245 patients switched from subcutaneous dupilumab 300 mg every other week to once-daily upadacitinib 30 mg at week 22. According to the study, patients on upadacitinib saw a baseline EASI score of 30.5 improve to 2.4 at week 24. Those who continued on the drug maintained this improvement with a score of 2.7 at week 16 of the OLE, and 91% of these patients reported an EASI score of 7 or less at the same time point. Additionally, researchers found that 73.6% of patients receiving continuous upadacitinib achieved EASI 90 and 54.2% achieved a Worst Pruritus-Numerical Rating Scale (WP-NRS) score of 0 or 1 in the extension analysis. Those patients who switched from dupilumab to upadacitinib in the OLE continued to demonstrate an improvement in EASI, according to the study, with a mean EASI score of 28.8 at baseline, 3.29 at week 24 of Heads Up and 1.09 at the end of the 16-week extension analysis. The proportion of patients that switched treatment and achieved EASI 90 increased from 66.4% at week 24 of Heads Up to 87.7% by the end of the 16-week analysis. This jump in EASI 90 was also seen in these patients within 4 weeks of switching biologics, according to the study. Additionally, the researchers found that the percentage of patients that switched treatments and achieved a WP-NRS of 0 or 1 increased from 33.3% to 66.7% after 4 weeks of treatment. The study reports that the safety profile of upadacitinib through the 16-week analysis was consistent with previously published phase 3 AD studies with no new safety risks. The most common adverse events reported in patients that switched from dupilumab to upadacitinib included acne, worsening AD, blood creatinine phosphokinase increase and nasopharyngitis. One patient in the study died due to bone tuberculosis, and this death was not considered to be related to the study drug, according to the researchers. “Upadacitinib provides greater efficacy compared with dupilumab, has a favorable benefit-risk profile, and patients, regardless of prior dupilumab response status, experienced improved outcomes when switched to upadacitinib,” Blauvelt and colleagues concluded. Read more about

Affibody Frequently Asked Questions (FAQ)

  • When was Affibody founded?

    Affibody was founded in 1998.

  • Where is Affibody's headquarters?

    Affibody's headquarters is located at Scheeles väg 2, Solna.

  • What is Affibody's latest funding round?

    Affibody's latest funding round is Loan.

  • How much did Affibody raise?

    Affibody raised a total of $21.26M.

  • Who are the investors of Affibody?

    Investors of Affibody include European Investment Bank, International Biotechnology Trust, Life Equity Sweden, Investor Growth Capital, HealthCap Venture Capital and 6 more.

  • Who are Affibody's competitors?

    Competitors of Affibody include Elusys Therapeutics, Acumen Pharmaceuticals, Elcelyx Therapeutics, Arcion Therapeutics, ERA Biotech and 13 more.

Compare Affibody to Competitors


AutekBio is a biotech firm headquartered in the Bay Area, US.


ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.

Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

Sonexa Therapeutics

Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Greenovation Biotech

greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.